BioQuest Appoints former CEO of Affinity VoIP Telecom, Ed Preble as Chief Technology Officer
BioQuest (OTC PINK:BQST) has appointed Ed Preble as Chief Technology Officer (CTO), following its recent acquisition of BotMakers, a conversational AI platform. This appointment marks BioQuest's strategic shift from biotechnology to AI automation technology.
Preble brings over 40 years of experience in technology innovation and business growth, with expertise in AI, SaaS, telecom automation, and enterprise infrastructure. He previously served as CEO of Affinity VoIP Telecom and was a professor of eCommerce at San Jose State University.
Following the BotMakers acquisition, BioQuest is expanding its AI-powered solutions including:
- Conversational AI agents for lead engagement
- Omnichannel social media automation
- AI-generated funnels and CRM automations
- Biotech-specific AI solutions for clinical communication
BioQuest (OTC PINK:BQST) ha nominato Ed Preble come Chief Technology Officer (CTO), a seguito della recente acquisizione di BotMakers, una piattaforma di intelligenza artificiale conversazionale. Questa nomina segna il passaggio strategico di BioQuest dalla biotecnologia alla tecnologia di automazione basata sull'IA.
Preble vanta oltre 40 anni di esperienza nell'innovazione tecnologica e nella crescita aziendale, con competenze in IA, SaaS, automazione delle telecomunicazioni e infrastrutture aziendali. In precedenza è stato CEO di Affinity VoIP Telecom e professore di eCommerce presso la San Jose State University.
In seguito all'acquisizione di BotMakers, BioQuest sta ampliando le sue soluzioni basate sull'IA, che includono:
- Agenti di IA conversazionale per l'engagement dei lead
- Automazione omnicanale dei social media
- Funnel generati dall'IA e automazioni CRM
- Soluzioni IA specifiche per la biotecnologia nella comunicazione clinica
BioQuest (OTC PINK:BQST) ha nombrado a Ed Preble como Director de Tecnología (CTO), tras su reciente adquisición de BotMakers, una plataforma de inteligencia artificial conversacional. Este nombramiento marca el cambio estratégico de BioQuest de la biotecnología a la tecnología de automatización basada en IA.
Preble aporta más de 40 años de experiencia en innovación tecnológica y crecimiento empresarial, con experiencia en IA, SaaS, automatización de telecomunicaciones e infraestructura empresarial. Anteriormente fue CEO de Affinity VoIP Telecom y profesor de comercio electrónico en la Universidad Estatal de San José.
Tras la adquisición de BotMakers, BioQuest está ampliando sus soluciones impulsadas por IA, que incluyen:
- Agentes de IA conversacional para la interacción con clientes potenciales
- Automatización omnicanal en redes sociales
- Funnels generados por IA y automatizaciones de CRM
- Soluciones de IA específicas para biotecnología en comunicación clínica
BioQuest (OTC PINK:BQST)는 최근 대화형 AI 플랫폼인 BotMakers를 인수한 후 Ed Preble를 최고기술책임자(CTO)로 임명했습니다. 이번 임명은 BioQuest가 생명공학에서 AI 자동화 기술로 전략적 전환을 하는 것을 의미합니다.
Preble는 AI, SaaS, 통신 자동화, 기업 인프라 분야에서 40년 이상의 기술 혁신 및 비즈니스 성장 경험을 보유하고 있습니다. 이전에는 Affinity VoIP Telecom의 CEO를 역임했으며 샌호세 주립대학에서 전자상거래 교수로 활동했습니다.
BotMakers 인수 이후 BioQuest는 AI 기반 솔루션을 확장하고 있으며, 주요 내용은 다음과 같습니다:
- 리드 참여를 위한 대화형 AI 에이전트
- 옴니채널 소셜 미디어 자동화
- AI 생성 퍼널 및 CRM 자동화
- 임상 커뮤니케이션을 위한 생명공학 특화 AI 솔루션
BioQuest (OTC PINK:BQST) a nommé Ed Preble au poste de Directeur Technique (CTO), suite à l'acquisition récente de BotMakers, une plateforme d'intelligence artificielle conversationnelle. Cette nomination marque le virage stratégique de BioQuest, passant de la biotechnologie à la technologie d'automatisation par IA.
Preble apporte plus de 40 ans d'expérience en innovation technologique et croissance d'entreprise, avec une expertise en IA, SaaS, automatisation des télécommunications et infrastructure d'entreprise. Il a précédemment été PDG d'Affinity VoIP Telecom et professeur de commerce électronique à l'Université d'État de San Jose.
Suite à l'acquisition de BotMakers, BioQuest étend ses solutions basées sur l'IA, comprenant :
- Agents conversationnels IA pour l'engagement des prospects
- Automatisation omnicanale des réseaux sociaux
- Funnels générés par IA et automatisations CRM
- Solutions IA spécifiques à la biotechnologie pour la communication clinique
BioQuest (OTC PINK:BQST) hat Ed Preble zum Chief Technology Officer (CTO) ernannt, nach der kürzlichen Übernahme von BotMakers, einer Plattform für konversationelle KI. Diese Ernennung markiert die strategische Neuausrichtung von BioQuest von der Biotechnologie hin zur KI-Automatisierungstechnologie.
Preble bringt über 40 Jahre Erfahrung in Technologieinnovation und Unternehmenswachstum mit, mit Fachkenntnissen in KI, SaaS, Telekommunikationsautomatisierung und Unternehmensinfrastruktur. Zuvor war er CEO von Affinity VoIP Telecom und Professor für E-Commerce an der San Jose State University.
Nach der Übernahme von BotMakers erweitert BioQuest seine KI-gestützten Lösungen, darunter:
- Konversationelle KI-Agenten zur Lead-Interaktion
- Omnichannel-Automatisierung in sozialen Medien
- KI-generierte Funnels und CRM-Automatisierungen
- Biotechnologie-spezifische KI-Lösungen für klinische Kommunikation
- Strategic pivot from biotech to high-growth AI automation sector
- Acquisition of BotMakers platform strengthens AI capabilities
- Appointment of experienced CTO with 40+ years of relevant expertise
- Expansion into multiple revenue streams through AI-powered solutions
- Complete departure from original biotech business model carries execution risks
- Significant organizational transformation may lead to integration challenges
From Biotech to Bots: BioQuest Doubles Down on AI Automation with New CTO and Vision for Intelligent Infrastructure
SAN FRANCISCO, CA / ACCESS Newswire / April 16, 2025 / BioQuest (OTC PINK:BQST), a former biotechnology and innovation company, today announced the appointment of Ed Preble as its new Chief Technology Officer (CTO). The announcement comes on the heels of BioQuest's acquisition of BotMakers, a cutting-edge conversational AI platform-firmly establishing BioQuest as a transformative leader in the conversational AI technology sector.
This strategic expansion marks a bold evolution of BioQuest's mission, placing the company at the powerful intersection of biotech, artificial intelligence, and intelligent automation.
"With BotMakers, we entered the conversational AI space. With Ed Preble, we're now positioned to define it," said Trent Daniel , CEO of BioQuest. "Ed is not just a CTO-he's a force for transformation. He builds the systems, teams, and strategies that take companies from potential to performance, and we couldn't be more excited to welcome him aboard."
Ed Preble: Architect of Innovation, Execution, and Scalable AI
With over 40 years of experience driving technology innovation and business growth, Ed Preble brings an elite combination of strategic vision, deep technical expertise, and entrepreneurial execution to BioQuest. His appointment reinforces BioQuest's commitment to dominating the conversational AI space with best-in-class platforms that combine automation, intelligence, and impact.
Ed's experience spans:
AI and SaaS innovation
Telecom and omnichannel automation
Real estate tech and enterprise infrastructure
High-growth startup leadership and M&A strategy
He holds degrees in Business and Economics and previously served as a university professor of eCommerce at San Jose State University -where he authored one of the earliest textbooks on digital transformation. He's a builder of platforms, a leader of agile teams, and a strategist who merges technical depth with business precision.
"Joining BioQuest is about more than technology-it's about building a category-defining future," said Preble. "Conversational AI isn't just a feature. It's the new interface for business, healthcare, biotech-everything. We're setting the standard."
Powering the Future of Intelligent Engagement
BioQuest's acquisition of BotMakers was a strategic leap forward. With Preble's leadership, the company is scaling rapidly to offer an integrated suite of AI-powered tools and platforms, including:
Conversational AI agents for lead engagement, qualification, and scheduling
Omnichannel social media automation
AI-generated funnels, CRM automations, and voice interaction systems
Biotech-specific AI solutions for clinical communication, research workflows, and patient engagement
These capabilities solidify BioQuest's place as a transformative leader in the global conversational AI technology sector, uniquely positioned to deliver across both digital and life science domains.
A Unified Vision for Innovation and Impact
With Preble as CTO, BioQuest will:
Expand its AI platform offerings into biotech, healthcare, and B2B sectors
Launch rapid MVPs and product iterations aligned with evolving market needs
Scale conversational interfaces that enhance both enterprise operations and customer experience
Drive automation-first strategies that reduce costs, increase engagement, and generate new revenue streams
"At BioQuest, we're combining the intelligence of biology with the intelligence of machines," said Preble. "We're not just automating interactions-we're creating ecosystems that learn, evolve, and deliver value at scale."
About BioQuest
BioQuest (OTC PINK:BQST) With the acquisition of BotMakers, BioQuest has emerged as a transformative leader in the conversational AI technology sector, building platforms that empower businesses to automate engagement, scale operations, and unlock new levels of efficiency and growth.
For more information, visit bioquestcorp.com
Media Contact
Tamares Davis
tdavis@botmakers.ai
1-866-753-8002
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Forward-looking statements are typically identified by words such as "anticipates," "believes," "expects," "intends," "plans," "projects," "seeks," "estimates," and similar expressions. They are not guarantees of future performance and are subject to risks, uncertainties, and other factors-some of which are beyond the company's control.
Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. BioQuest, Inc. and BotMakers, Inc. undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
SOURCE: BioQuest
View the original press release on ACCESS Newswire
FAQ
What strategic shift has BioQuest (BQST) announced with its new CTO appointment?
What experience does Ed Preble bring to BioQuest (BQST) as the new CTO?
What AI solutions will BioQuest (BQST) offer under Preble's leadership?
How does BioQuest (BQST) plan to expand its AI platform offerings?
